• Hormone replacement therapy for oestrogen deficiency symptoms in postmenopausal women more than 1 year postmenopause. • Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis. (See also Section 4.4)
AstraZeneca announced an agreement to acquire Neogene Therapeutics Inc (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts) that offer a novel cell therapy approach for targeting cancer
Incyte announced positive topline results from its randomized, vehicle-controlled, pivotal Phase III TRuE-AD3 study evaluating the safety and efficacy of Opzelura (ruxolitinib cream) in children (age at least 2 to <12 years) with atopic dermatitis (ad)
Celgene Corporation and Acceleron Pharma Inc. announced that Celgene has submitted a Biologics License Application (BLA) for luspatercept, an erythroid...
GlaxoSmithKline plc and Innoviva, Inc. announced that the FDA has approved once-daily, single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), under...
Turner syndrome affects 25-50 per 100,000 females and can involve multiple organs through all stages of life, necessitating multidisciplinary approach to care.